BIOMAT Database Logo BIOMAT Database Logo

Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy. 1996

G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
Istituto di Medicina Clinica, University of Padova, Italy.

The clinical significance of serum procollagen type III peptide, a marker of active fibrogenesis, was evaluated in 110 hepatitis B surface antigen positive patients with chronic hepatitis (32 chronic persistent hepatitis, 60 chronic active hepatitis, and 18 active cirrhosis), selected on the basis of active viral replication and biochemical activity, including 54 cases treated with interferon-alpha. At presentation the procollagen type III peptide level serum was above normal in 48 (44%) of the 110 patients and the median value was significantly higher than that of healthy carriers with normal transaminases and histology (P < 0.000005). Semiquantitative histological evaluation showed a significant correlation between serum procollagen type III peptide levels and necrosis/inflammation in the subgroup of patients with chronic active hepatitis, but no relationship with the score of fibrosis. Among patients treated with interferon-alpha and with increased fibrogenic activity (indicated by high pretreatment serum levels of procollagen type III peptide), peptide levels were significantly decreased when pretreatment levels were compared with those at 12 months after therapy withdrawal, both in responders to interferon (P = 0.022) and non-responders (P = 0.012). However, serum procollagen type III peptide levels normalized in 75% of responders to interferon with sustained serological and histological remission of liver disease, but in only 21% of non-responders (P = 0.02). These results obtained in a well-defined population suggest that serum procollagen type III peptide is a better marker of active fibrogenesis and inflammation than an indicator of the extent of fibrosis, and that interferon may reduce active liver fibrogenesis in chronic hepatitis B independently of its effect on viral replication. However, a consistent proportion (56%) of our chronic hepatitis B patients had normal serum procollagen type III peptide levels at presentation, thus precluding the clinical use of this marker both for diagnosis of liver injury and for monitoring the therapeutic response to interferon.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity.
January 1987, Hepatology (Baltimore, Md.),
G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy.
January 1996, The Italian journal of gastroenterology,
G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration.
April 1989, British journal of rheumatology,
G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
[Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B].
December 2002, Taehan Kan Hakhoe chi = The Korean journal of hepatology,
G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity.
June 1991, European journal of clinical investigation,
G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection.
September 1994, Digestive diseases and sciences,
G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
Serum type-III-procollagen and laminin concentration after interferon therapy in chronic myeloproliferative disorders.
January 1988, Acta medica Hungarica,
G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests.
March 1991, Journal of hepatology,
G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
January 2003, Hepato-gastroenterology,
G Giustina, and G Fattovich, and M De Paoli, and M Guido, and S Favarato, and M Rugge, and A Alberti, and A Ruol, and M Plebani
[Significance of type III serum N-terminal peptide procollagen assay in chronic viral hepatitis C].
January 1994, Gastroenterologie clinique et biologique,
Copied contents to your clipboard!